ICU Medical: A Healthcare Stock with Strong Growth and Value

ICU Medical is a company that develops, manufactures, and sells medical devices and consumables for critical care, oncology, and infusion therapy. The company’s products include intravenous (IV) solutions, sets, connectors, pumps, and systems; needle-free IV connectors; closed system transfer devices for hazardous drugs; and custom infusion sets ICU Medical also provides contract manufacturing services for medical device companies.

Stock Performance

ICU Medical is traded on the NASDAQ under the symbol ICUI. The stock has been performing well and has gained 16.6% year-to-date as of August 11, 2023. The stock closed at $142.42 per share, up 0.4% from the previous day. The stock has a 52-week range of $128.90 to $212.43, and an average volume of 230,291 shares. The market cap of the company is $3.746 billion, and the beta is 0.70, indicating that the stock is less sensitive to market movements than the average stock.


According to its latest quarterly report, ICU Medical had a revenue of $321.6 million for the three months ended June 30, 2023, up 14.7% year-over-year. The company reported a net income of $10.5 million, or $0.42 per diluted share, compared to a net loss of $8 million, or $0.32 per diluted share, in the same period last year. The company had a cash balance of $286.1 million and total assets of $1.64 billion as of June 30, 2023. The company had total liabilities of $383.9 million and total equity of $1.26 billion as of June 30, 2023. The company had an earnings per share of $0.42 and a dividend yield of 0%4.


ICU Medical has been growing its revenue and earnings through organic growth and strategic acquisitions. Some of the factors that could drive its future growth include:

  • Increasing demand for its products and services in the critical care, oncology, and infusion therapy markets, especially amid the COVID-19 pandemic.
  • Expanding its international presence and customer base in emerging markets such as China, India, Brazil, and Mexico.
  • Leveraging its innovation capabilities and patent portfolio to launch new and improved products and solutions that meet the evolving needs of healthcare providers and patients.
  • Enhancing its operational efficiency and profitability by optimizing its manufacturing footprint, supply chain, and cost structure.


However, ICU Medical also faces some challenges and risks that could limit its growth potential and valuation. Some of these include:

  • Facing intense competition from other medical device companies that offer similar or alternative products and services.
  • Experiencing fluctuations in its revenue and margins due to changes in customer preferences, market conditions, pricing pressures, regulatory requirements, and reimbursement policies.
  • Being exposed to various legal, regulatory, compliance, quality, safety, environmental, and cybersecurity risks that could result in litigation, fines, penalties, recalls, or reputational damage.
  • Having a high dependence on a few key customers and suppliers that could adversely affect its business if they terminate or reduce their relationships with the company.


ICU Medical is a healthcare stock that offers exposure to the growing markets of critical care, oncology, and infusion therapy. The company has been delivering strong financial performance and growth through its diversified product portfolio, global footprint, innovation capabilities, and operational excellence. However, the company also faces significant competition and uncertainties that could pose challenges to its future performance and valuation. Therefore, investors should carefully weigh the pros and cons of investing in this stock.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button